Medidata took a look at how eCRF design complexity correlates with the number of migrations performed while a study is actively collecting subject data.
Quite often, during the course of a clinical trial, the need arises to update case report forms (CRFs). In the world of electronic data capture, these forms are electronic, or “eCRFs.” Such updates can arise from protocol amendments, changes to the eCRF specification requirements or to the logic that automates the entry or verification of data in the study. Creating a new version of the eCRF and migrating subject records to that version is time consuming and costly, and can add additional burden-not only to sponsor and CRO personnel but also to sites. It is therefore imperative to keep such eCRF updates and migrations to the necessary minimum.
With this in mind, we took a look at how eCRF design complexity correlates with the number of migrations performed while a study is actively collecting subject data. Our expectation was that a correlation exists, and this was confirmed by the data. As you can see in the graph, the more complex the eCRF design the more likely it was to require an update during the course of the study. The eCRF design complexity is based on the number of unique eCRF pages, edit checks (custom and standard) and derivations included in the design. The studies included in the dataset were grouped based on their eCRF design complexity and the average number of migrations performed per study. Our findings indicated that the studies with the highest eCRF complexity also performed more migrations, which results in more time spent maintaining the eCRFs.
The study-planning phase should take into account factors that will affect eCRF design efficiency. Having a lower eCRF design complexity will have a positive downstream effect by mitigating the need for migrations and lessening burden on study teams and site staff during the course of the study.
-Medidata Solutions
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Twice-Yearly Lenacapavir Injections Significantly Reduce HIV Risk, PURPOSE 2 Trial Shows
November 13th 2024Full Phase III PURPOSE 2 trial results suggest that twice-yearly lenacapavir could revolutionize HIV prevention by offering a convenient and effective long-acting option for individuals at risk of infection.